Alcoholic Cirrhosis
21
4
4
6
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
19.0%
4 terminated out of 21 trials
60.0%
-26.5% vs benchmark
14%
3 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (21)
SAMe Trial for Patients With Alcoholic Cirrhosis
Validation of the Procedure of Early Liver Transplantation in Alcoholic Hepatitis Resisting to Medical Treatment
Mild Hypothermia and Acute Kidney Injury in Liver Transplantation
Optimized Remission in Alcohol-related Liver Cirrhosis
Safety & Efficacy of Baclofen for Alcohol Withdrawal in Chronic Liver Disease With Active Alcohol Consumption
Long-term Follow-up of Patients With Alcoholic Liver Cirrhosis Who Had Administered Cellgram-LC in PMC-P-07 Study
Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis
Study of Genetic Determinants in Alcoholic Hepatitis and Establishment of a Multicenter Prospective Cohort of Patients With Alcoholic Liver Disease
Study of Decompensated Alcoholic Cirrhosis Treatment by Stem Cells
Early Detection of Alcoholic Liver Disease
Value on Survival of Liver Volume After an Acute Decompensation of an Alcoholic Cirrhosis
Pangenomic Study During Alcoholic Cirrhosis
Zinc Supplementation in Alcoholic Cirrhosis
EUS Based Prevalence of Chronic Pancreatitis in Alcoholic Cirrhosis
Alcohol Biomarker Study
National Cohort of Uncomplicated Alcoholic Cirrhosis
Indocyanine Green and Portal Pressure in Viral and Alcoholic Cirrhotic Patients With Hepatocarcinoma
Hemodynamic Effects of Chronic Administration of Spironolactone and/or Propranolol in Alcoholic Cirrhotic Patients
Randomised Open-label Multicenter Study Evaluating Ciprofloxacin in Severe Alcoholic Hepatitis
Phlebotomy and Risk of Hepatocellular Carcinoma in Patients With Compensated Alcoholic Cirrhosis